[Regulation of angiogenesis-expression of VEGF receptors].
Angiogenesis, the formation of new blood vessels from pre-existing endothelium, is a crucial process for tumor growth, metastasis and inflammation. Therefore, it is focused on the anti-tumor therapy to prohibit angiogenesis in animal model and clinical studies. Eicosapentaenoic acid (EPA 20: 5,n-3) can restrain tumor growth and inflammation. In this paper, we examined the effects of EPA on tube formation. In EPA-pretreated endothelial cells angiogenesis was attenuated and also proliferation induced by VEGF, but not by b-FGF, was suppressed. The reason why EPA suppressed endothelial cell proliferation induced by VEGF was that EPA selectively inhibited the expression of KDR. As we mentioned, the regulation of angiogenesis in vivo may be involved in the expression of VEGF receptors.
Morita
I
I
Department of Physiological Chemistry, Graduate School, Tokyo Medical and Dental University, Japan. morita.cell@dent.tmd.ac.jp
D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002455:Cell Division; D003930:Diabetic Retinopathy / Q000188:drug therapy; D015118:Eicosapentaenoic Acid / Q000494:pharmacology / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000166:cytology; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000503:physiopathology*; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism / Q000502:physiology*; D017978:Receptors, Growth Factor / Q000378:metabolism / Q000502:physiology*; D040262:Receptors, Vascular Endothelial Growth Factor
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D017978:Receptors, Growth Factor; D015118:Eicosapentaenoic Acid; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor